Novartis AG (NYSE:NVS) Q3 2023 Earnings Call Transcript

Right now, we have a broad number of agents, we’ll be covering that in the upcoming R&D Day. But we’ve really built up the clinical trial network and the internal research and technical development expertise to have a portfolio of radioligand therapies. Of course, we lifecycle manage Pluvicto, we’ve lifecycle manage Lutathera. We have our FAPI currently in Phase 2 studies. We have our [indiscernible] in Phase 2 studies. We have an integrin. We’re moving forward to folate, as well as, as you mentioned, working on peptide, other peptide, fab fragment and antibody-based technologies that would allow us to use radioligand with these antibodies, including, I would say, established ADC targets, where, if we can get the biology right, there could be the opportunity that radioligand therapies have an improved therapeutic index given the safety profile that we’ve seen for RLTs versus ADCs. That’s to be proven, but certainly, you have that opportunity when you build out that development portfolio.

And then I think third is having the commercial infrastructure to actually be able to deliver this, manage this. It takes IT systems, patient flows, and expertise on the ground that we’ve really consistently now built up around the world. So I think together, these three things consistently built with years now of investment and effort, give us a substantial lead versus any competitor. But that said, we take competition very seriously. We agree that there are many people now looking at the space, and we have to continue to raise the bar on how we execute to ensure that we remain leaders in radioligand therapy in the long run. And I think that’s the last question. So I appreciate everybody’s time today. We look forward to giving you an update again at the R&D Day.

I hope everyone will be able to join. And thank you again for your interest in the company. We’ll continue to work hard every day to keep develop — delivering value for all of you, our shareholders. All the best.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.